Aims: The aim of the study deals with the design, development, and comparative stability studies of optimized formulations as well as potential formula and process optimization trials of novel orlistat liposomal dispersion. All the experimental studies were evaluated for stability study profiles with respect to physical and chemical key parameters such as physical appearance, pH, density, drug entrapment efficiency, drug content, particle size, polydispersity index and zeta potential. The stability study was carried out at different temperature storage conditions. Materials and Methods: Formula optimization studies were utilized to investigate the impact of different molar ratios of orlistat, soya phosphatidylcholine, and cholesterol. Process optimization studies were also performed to comprehend the effect of variable stirring time, sonication time, and centrifugation time on the physical and chemical factors. Orlistat liposomal formulations were prepared using ethanol injection method. Results and Discussion: Percentage entrapment efficiency of F30 and F31 has 90.6 ± 0.3% and 89.0 ± 0.2% and average particle size of 847.9 nm and 848.1 nm, respectively, and rest of the physical and chemical parameters were satisfactory. Conclusions: The basic aim of the study was achieved with maximum % entrapment efficiency with smaller particle size. The optimized formulations have satisfactory physicochemical parameters at the initial time point and retained similar during stability at long-term storage conditions up to 6 months. Optimized formulations were stable up to 1 month at accelerated storage condition, but there was a significant change observed at 2 and 3 months.
INTRODUCTION
L iposomes are one of the most potent candidates for drug carrier systems. However, the efficacy of liposomes as a drug delivery system has not yet been truly established. One of the reasons for this is the instability of vesicles, particularly in biological media (i.e., blood and gastrointestinal [GI] tract.). [1] In general, in the early stages of development, freshly prepared liposomes are used. However, from a pharmaceutical point of view, it is important to demonstrate that liposomes can be stored for a long period of time. Degradation process particularly oxidation and hydrolysis may change the properties of an aqueous liposome dispersion. [2] Especially, with liposomal product to see the market, it should be stable during the shelf life (storage or transport). In general, a shelf life of at least 1 year is a minimum pre-requisite criterion for a commercial product. First, leakage of drug from the vesicles may take place into the extra liposomal compartment. Second, there is a possibility of liposomal aggregation and/or fusion, which leads to the formation of larger particles. [3] [4] [5] [6] These parameters will alter the in vivo fate, affecting therapeutic index of the drug. Hydrolysis of phospholipids is one of the parameters likely to cause the formation of fatty acids and lysophospholipids. [7, 8] Although under dehydrated storage, there is least possibility of the formulation to encounter hydrolytic degradation. Another aspect to be considered is liposome oxidation. [9] Oxidation of phospholipids can be minimized using antioxidants or an inert atmosphere. [10] The use of herbal remedies carries along problems, such as low solubility and hence limited absorption and bioavailability. Such biologically active compounds are also prone to in vivo hydrolysis, oxidation, and photolysis, urging the need for stabilization platforms. [11, 12] Technologies such as liquid crystal (LC) systems, polymeric and solid lipid nanoparticles, precursors systems for LC, liposomes, and microemulsions have been reported to overcome such limitations. [13] Liposomes have been extensively studied and are used in the treatment of several diseases. Liposomes improve the therapeutic efficacy by enhancing drug absorption while avoiding or minimizing rapid degradation and side effects, prolonging the biological half-life, and reducing toxicity. [14] Liposomes are colloidal vesicles ranging from few nanometers to several micrometers in diameter with one or several lipid bilayers surrounding an inner aqueous compartment. [15, 16] Liposomes are biodegradable, biocompatible, nontoxic, and non-immunogenic. Hydrophilic drugs can be encapsulated in the aqueous core, and lipophilic drugs can be entrapped in the lipid bilayers. [17] Several factors such as aqueous volume, membrane rigidity, surface area, and preparation methods of liposomes have influence on the encapsulation efficiency (EE) of liposomes. [18, 19] Obesity refers to a condition of an abnormal accumulation of body fat mass (body mass index >30 kg/m 2 ) and is often associated with serious medical conditions, including impaired glucose tolerance, insulin resistance, increased blood pressure, altered lipid levels, and other chronic conditions. [20] Although the etiology of obesity is complicated and not well understood, obesity is likely due to an increase in energy excess that results from caloric intake that exceeds energy expenditure. [21] Orlistat is an anti-obesity agent and acts locally in the GI tract to inhibit lipase, an enzyme that is necessary for the digestion of long-chain triglycerides. Orlistat can also impact cardiovascular risk factors including total and low-density lipoprotein cholesterol, blood pressure, and plasma glucose when accompanied by dietary changes. [22] It is minimally absorbed and helps to reduce body weight by inhibiting absorption of ingested dietary fat by approximately 30%. It can be a useful adjunctive therapy for weight loss and maintenance in obese patients willing to undergo changes in diet and exercise routines. [23] Orlistat, being highly hydrophobic in nature, is an ideal candidate drug for liposome encapsulation. In the present work, two different preparation techniques for liposomes have been attempted for this challenging endeavor.
In our earlier study, the objective was to formulate the orlistat liposomal colloidal dispersion of various compositions. Formula optimization studies were carried out to see the effect of variation in the active pharmaceutical ingredient (API), lipid and cholesterol concentrations on the physical as well as chemical characteristics of the liposomal formulations. Process optimization studies were also accomplished and evaluated to comprehend the effect of different batch sizes, altered stirring time, ultrasonication time, centrifugation time, etc., on the physical as well as chemical parameters of the liposomal vesicles. We had also studied the impact of alternate method like thin film hydration method on the physical parameters as well as on the % EE and drug content. [24] In the present study, our goal was to evaluate and characterize the comparative stability study profiles of novel orlistat liposomal formulations and conclude the study. The stability studies were accomplished for formula and process optimization batches as well as optimized batches of the orlistat liposomal dispersion with respect to the physical and chemical parameters. In this investigation, we attempted to develop and evaluate the stability study profiles of the key impact of various formulations and process on the physical appearance, pH, density, drug entrapment efficiency, drug content, particle size, polydispersity index (PDI), and zeta potential. The stability study was carried out at different temperature storage conditions.
MATERIALS AND METHODS

Materials
Orlistat API was received as a gift from Murli Krishna Pharma Pvt. Ltd., Pune. PHOSPHOLIPON 90 G (Soybean phosphatidylcholine) is also received as a gift sample from Lipoid Co., Germany. Cholesterol was purchased from Suvchem Laboratory, Mumbai. All other chemicals and reagents used were of analytical grade and used as such without further purification. Water purified by Milli Q system was used for experiments.
Preparation of orlistat-loaded liposomes by ethanol injection method
Orlistat liposomal formulations with different molar ratios were prepared using the ethanol injection method as it gives better entrapment supported by percentage entrapment efficiency study. Accurately weighed and dissolved phospholipon 90 G, cholesterol, and orlistat (in molar ratios) one after other in minimum quantity of ethanol under stirring in a glass beaker. Purified water was taken in other glass beaker under stirring by magnetic stirrer (Make: Remi Elektrotechnik Ltd., Mumbai, Model: 5 MLH Plus) at 1500 rpm at 36-38°C warming temperature. Then, the above orlistat dissolved lipid solution was added in dropwise manner with the help of syringe to the warm purified water (aqueous phase) in 3 min time under stirring. Continued stirring at 1500 rpm for evaporation of ethanol for about 30 min at 36-38°C dispersion temperature. Turbid/translucent uniform slurry was obtained. The resulting dispersion was ultrasonicated at power output of 100 with pulser "ON" at 30% by a probe tip sonicator (Make: Biologics Inc., USA, Model: 300 V/T) for about 5-7 min. The probe tip of the ultrasonic homogenizer was just dipped into the dispersion (care should be taken such that the probe tip does not touch the bottom of the glass beaker during sonication). The ambient temperature was maintained during sonication using ice cubes under the beaker in different containers. Excess heat may be generated during sonication, which may damage the lipids. Uniform liposomal dispersion was obtained after sonication. It was then stored at 2-8°C in refrigerator.
Characterization and evaluation of liposomes
Physical appearance, pH, and density
Clarity of the formulations was inspected under light against white and black background in a well-lit cabinet for appearance and clarity. pH of the formulations was measured using digital pH meter. [25] Density (wt/ml) of the liposomal formulations was determined using pycnometer.
Determination of drug entrapment efficiency (% EE)
Ultracentrifugation method was used to determine the EE. The liposomal suspension was subjected for centrifugation at higher speed for a definite time. Later, the supernatant and sediment (pellet) were collected and analyzed for the drug content. [26] Orlistat liposomal dispersion (approx. 1.4 ml) taken in Eppendorf and centrifuged in Multifuge 3S-R (Make: Heraeus, Germany) at 14,500 rpm for about 2 h for phase separation. This process was used for the optimized formulation trials. The drug was then estimated using HPLC system (Make: Dionex, USA, Model: Ultimate 3000) from the supernatant and pellet phase after centrifugation process. Methanol was used as a diluent for solubilization of supernatant as well as pellet and then taken the absorbance. The drug entrapment efficiency was calculated using the following formula:
Free drug content (%) 100 efficiency Total amount of drug added %
Entrapped drug in vesicles % 100 efficiency Total amount of drug added % × =
Drug content
The assay of liposomal formulation was determined by dissolving liposomes in methanol as a diluent. Volume was made up to the mark with methanol in volumetric flask and mixed well to ensure the solubility of drug. This solution was then estimated for drug content using HPLC system with acetonitrile, phosphoric acid, and water (860:0.05:140) as a solvent system at a flow rate of 1.0 ml/min. The 20 µL of sample solution was injected, and the absorption was detected at a wavelength of 195 nm.
Digital microscopy
Digital microscope is a variation of a traditional optical microscope that uses optics and a digital camera to output an image to monitor by means of software running on a computer. Digital microscope used in the study was manufactured by Motic, Hong Kong (Model: BTB24-12A) with built-in digital camera with CMOS and CCD imaging sensors. It has inbuilt LED light source and image analysis software Motic Images Plus 2.0 ML with resolution 3.0 MP.
Zeta potential, mean particle size, and size distribution (PDI)
The PDI value is important in that it shows the size distribution of the liposomes, which can correlate to stability. A PDI value of 1.0 indicates a very broad size distribution or presence of large particles or aggregates, which could sediment. An optimum PDI value is 0.30 or less, signifying that 66.7% of all nanovesicles are the same size.
[27] The zeta potential is used to evaluate the dispersional stability of liposomal formulations. It characterizes the particle surface charge and gives an indication about repulsive forces between particles, thus allowing one to predict the stability of dispersions. [28] Zeta potential, average particle size (in nanometers), and particle size distribution (as PDI) of the liposomal suspension were measured by zeta potential analyzer model Zeta PALS (Brookhaven Instruments Co., NY, USA) at 25°C with a dynamic light scattering method. The sample was placed in a quartz cuvette, and the scattered light was detected at a scattering angle (θ) of 90° for particle size measurement. The vesicle size and zeta potential evaluation of liposomal formulations were performed and described by the volume mean diameter in nanometers and zeta potential in millivolts using software. [29] Each liposomal dispersion sample was diluted with distilled water before analysis until the appropriate concentration of particles was achieved.
Stability studies of liposomal suspension
The particle size, size distribution, change in mean particle size with time, and physical appearance of the liposomal suspension are sensible indicators of the kinetic stability of liposomal suspensions. Drug entrapment efficiency, drug content, zeta potential, pH, and density were also evaluated during stability studies for various formulations of orlistat liposomal suspension. The stability studies were accomplished for potential formula and process optimization batches as well as optimized batches of the orlistat liposomal dispersion with respect to the physical and chemical parameters of the liposomal dispersion.
Comparative stability studies were carried out at accelerated storage conditions (25°C ± 2°C, 60% RH ± 5% RH) for up to 1, 2, and 3 months. Long-term storage conditions (5°C ± 3°C) were carried out for up to 1, 2, 3, and 6 months for optimized formulations. Comparative stability studies were also carried out at long-term storage conditions (5°C ± 3°C) for up to 3 months for potential formula and process optimization batches. 25 ml each of formulation samples were kept in HDPE bottle at sealed condition at abovementioned time intervals. The samples were withdrawn, examined visually for the evidence of discoloration, and evaluated for its physical and chemical stability. The stability data was compiled and compared with the initial parameters of the liposomal suspension.
RESULTS AND DISCUSSION
In general, the shelf life stability of liposomes is determined by the physical and chemical stabilities (uniformity of size distribution and EE, and minimal degradation of all compounds, respectively). By optimizing the size distribution, pH, and ionic strength, liquid liposome formulations can be made stable. As phospholipids usually form the backbone of the bilayer, their chemical stability is important. Two types of chemical degradation reactions can affect the performance of phospholipid bilayers: Hydrolysis of the ester bonds linking the fatty acids to the glycerol backbone and peroxidation of unsaturated acyl chains (if present). The oxidation and hydrolysis of lipids may lead to the appearance of short-chain lipids, and then, soluble derivatives will be formed in the membrane, resulting in the decrease of the quality of liposome products. [30] Moreover, physical processes such as aggregation/flocculation and fusion/coalescence that affect the shelf life of liposomes can result in loss of liposome-associated drug and changes in size. Aggregation is the formation of larger units of liposomal material; these units are still composed of individual liposomes. In principle, this process is reversible, for example , by applying mild shear forces, by changing the temperature, or by binding metal ions that initially induced aggregation. However, the presence of aggregation can accelerate the process of coalescence of liposomes, which indicates that new colloidal structures are formed. [31] As coalescence is an irreversible process, the original liposomes cannot be retrieved. A colloidal dispersion is often thermodynamically unstable. Spontaneous processes occur in the direction of decreasing Gibbs free energy; therefore, the separation of a two-phase dispersed system to form two distinct layers is a change in the direction of decreasing Gibbs free energy. There is more surface energy in a liposome suspension when the dispersed phase is in a highly subdivided state than when it is in a coarser state of subdivision. The central feature of coalescence is the fact that the total surface area is reduced in the coarsening process of thermodynamically unstable liposome dispersion, while there is no reduction of surface in aggregation, although certain surface sites may be blocked at the points at which the smaller particles touch. [32] List of formula and batch details of stability batches of liposomal formulations are tabulated in Table 1 . The two optimized formulations were kept for the stability studies at accelerated storage conditions (25°C ± 2°C, 60% RH ± 5% RH) up to 3 months and long-term storage conditions (5°C ± 3°C) up to 6 months. The physicochemical parameters of F30 and F31 are presented in Tables 2 and 3 , respectively. Physicochemical parameters of potential formula and process optimization batches were also carried out at longterm storage conditions (5°C ± 3°C) for up to 3 months, and the details are given in Tables 4-11 .
Based on the stability study data of optimized formulations of B. No. F30 and F31, there were no significant differences observed for physical as well as chemical parameters for longterm storage conditions (5°C ± 3°C) for up to 6 months. Physical appearance, pH, and density of both the batches were retained as similar to initial. The physical appearance of the liposome formulations seemed unchanged, and neither sedimentation nor flocculation was observed indicating the high physical stability of the liposomal system in general. Percentage drug entrapment efficiency, assay, average particle size, PDI, and zeta potential were also satisfactory up to 6 months. However, there were significance differences observed in physicochemical parameters at accelerated storage conditions Data are represented as mean ± SD (n=3) (25°C ± 2°C, 60% RH ± 5% RH) for both the batches. Both the batches were stable physically and chemically up to 1 month that accelerated storage conditions and thereafter changes observed in physical consistency and pH up to 3 months. There was no significant impact observed on % EE, but significant variation in assay was observed for both the batches in 2 and 3 months' time point. This may be because of separation and uneven consistency of the dispersion. Particle size of both the batches was increased significantly in 2 and 3 months' time point. It has been earlier reported that the chemical hydrolysis may lead to an increase in particle size [33] and to an increase in permeability of liposomal bilayers. [34] Zeta potential of both the batches was satisfactory up to 3 months. Digital micrographs [ Figures 1 and 2 ] revealed that the liposomes were spherical in shape and the formed vesicles were in the form of individual particles with sharp boundaries. The photographs were taken for the optimized liposomal formulations. The micrographs showed here attest successful formation of lipid vesicles using ethanol injection method.
Stability study of formula optimization batches like low lipid and high API concentration trial (F17) has some big white particles observed in the turbid dispersion at initial time point. It may be due to the higher API concentration in the suspension. % EE, drug content, and particle size of the suspension were satisfactory. Zeta potential was on lower side. All the parameters remained comparable up to 3 months. High lipid and low API concentration trial (F18) observed uniform dispersion with low % EE, satisfactory particle size, zeta potential, and better PDI at initial time point. % EE was significantly and subsequently increased in 1.5 and 3 months. The particle size of liposomes was also increased in 3 months. This may be due to low API content in the suspension which was further entrapped within the high amount of lipidic core. Low cholesterol content (F19) was observed uniform dispersion with low % EE, satisfactory particle size, PDI, and comparatively low zeta potential at initial time point. % EE was significantly increased in 1.5 and 3 months. Other parameters were comparable up to 3 months. Uniform dispersion obtained in high cholesterol trial (F20) with satisfactory % EE, particle size, and zeta potential but larger PDI at initial. Some small white particles were observed in turbid dispersion and % EE was subsequently increased in 1.5 and 3 months.
Process optimization trials such as high stirring time (F21 and F22) had observed uniform dispersion with satisfactory % EE, drug content, average particle size, and zeta potential but larger PDI. Similar parameters were retained up to 3 months. High sonication trials (F23 and F24) had observed some big white particles in turbid dispersion at the initial time point, and later, also some small white particles were observed in 1.5 and 3 months. F23 was seen with satisfactory % EE, particle size, PDI, and zeta potential at initial, and further, it was retained up to 3 months. F24 was found low % EE and high drug content but satisfactory particle size, PDI, and zeta potential at initial and consequently increased % EE, particle size, and high drug content in 1.5 and 3 months. Therefore, it can be concluded that the very high ultra-sonication time was not suitable for this drug. The vesicles may get disrupted and drug is not entrapped considerably into the lipids.
CONCLUSION
Orlistat API is highly unstable molecule at room temperature, and hence, the storage is recommended in the refrigerator. In the present investigation, we have designed, formulated, optimized, and evaluated the successful entrapment of orlistat into liposomes with respect to its physical as well as chemical characteristics. The objective of the study has been achieved by means of maximum % drug entrapment efficiency with appropriate vesicle size and other physical and chemical stability of the liposomes as well. Physical appearance, pH, density, % drug entrapment efficiency, assay, particle size, PDI, and zeta potential of initial samples of both the optimized formulations, namely F30 and F31, were satisfactory and remained satisfactory up to 6 months at long-term storage conditions (2-8°C). Both the trials were stable up to 1 month at accelerated conditions (25°C/60% RH), but there was significant change observed after 2 and 3 months in physical as well as chemical parameters.
To protect from light and degradation, the drug was encapsulated in the form of liposomes, thereby improving the stability of the formulations. Optimization studies revealed the lipid and cholesterol concentration significantly affect the drug entrapment and size of the vesicles. There was significant change observed in some potential formula and process optimization trials during stability studies at 2-8°C up to 3 months.
From the study, it can be concluded that the ethanol injection method is suitable and acceptable process for the manufacturing of orlistat liposomes and to be stored at 2-8°C.
